ライフサイエンスコーパス: renal cell carcinoma

1 CNS hemangioblastomas, pheochromocytoma, and renal cell carcinoma).

2 or sunitinib in patients with non-clear cell renal cell carcinoma.

3 ant p.E318K also predisposes to melanoma and renal cell carcinoma.

4 as a radioimaging agent for CAIX-expressing renal cell carcinoma.

5 t-line treatment in patients with metastatic renal cell carcinoma.

6 including sporadic and inherited clear cell renal cell carcinoma.

7 in previously treated patients with advanced renal cell carcinoma.

8 t to delay disease progression in clear cell renal cell carcinoma.

9 nts with advanced or metastatic, clear-cell, renal cell carcinoma.

10 prediction of recurrence risk in clear cell renal cell carcinoma.

11 d-line treatment in patients with metastatic renal cell carcinoma.

12 nib is warranted in patients with metastatic renal cell carcinoma.

13 itor, in patients with metastatic clear cell renal cell carcinoma.

14 tumor perfusion in patients with metastatic renal cell carcinoma.

15 controversial in the treatment of metastatic renal cell carcinoma.

16 rgeted therapies in patients with metastatic renal cell carcinoma.

17 sts a deletion breakpoint described in human renal cell carcinoma.

18 tastatic tissue specimens from patients with renal cell carcinoma.

19 in the progression and clinical prognosis of renal cell carcinoma.

20 be (chRCC, also known as kidney chromophobe) renal cell carcinoma.

21 on correlates with poor clinical outcomes in renal cell carcinoma.

22 he optimal approach in metastatic clear cell renal cell carcinoma.

23 or previously treated patients with advanced renal cell carcinoma.

24 or, is an effective treatment for metastatic renal-cell carcinoma.

25 during the study period, all from metastatic renal-cell carcinoma.

26 gnaling as a potential therapeutic target in renal-cell carcinoma.

27 3 studies involving patients with metastatic renal-cell carcinoma.

28 s: 9 patients with clear cell subtype of the renal cell carcinoma, 5 patients with oncocytoma and 5 p

29 In renal cell carcinoma, 8 samples reduced the list of clon

30 nitiation of systemic therapy for metastatic renal-cell carcinoma; a decision that was made at the di

31 r prediction of local tumor recurrence after renal cell carcinoma ablation.

32 n of local tumor recurrence in patients with renal cell carcinoma after thermal ablation.

33 expressed in kidney, and is downregulated in renal cell carcinoma; also, its low expression correlate

34 s </= 10% of pheochromocytoma or early-onset renal cell carcinoma and </= 40% of CNS hemangioblastoma

35 to uveal melanoma, mesothelioma, meningioma, renal cell carcinoma and basal cell carcinoma.

36 ratumoral heterogeneity of a pair of primary renal cell carcinoma and its lung metastasis.

37 was lung cancer in seven patients (27%) and renal cell carcinoma and sarcoma in five patients each (

38 gnostic factor for survival in patients with renal cell carcinoma and the galectin-1-CXCR4 axis may s

39 ater with completely resected non-metastatic renal-cell carcinoma and adequate cardiac, renal, and he

40 r that proves effective in treating advanced renal-cell carcinoma and liver cancer.

41 inguish between clear cell and papillary RCC renal cell carcinoma , and it provides insights regardin

42 iminate between clear cell and papillary RCC renal cell carcinoma , and it yielded the following: sen

43 inating between clear cell and papillary RCC renal cell carcinoma , and results were validated by usi

44 bout the genetic basis of sporadic papillary renal-cell carcinoma, and no effective forms of therapy

45 Common metastatic sites of renal cell carcinoma are the lungs, lymph nodes, bones a

46 Non-clear cell renal cell carcinomas are histologically and genetically

47 aled that diffuse large B cell lymphomas and renal cell carcinomas are particularly susceptible to GP

48 ys, and tumor evolution and heterogeneity in renal cell carcinoma, as well as the most recent advance

49 second-line targeted therapy for metastatic renal cell carcinoma at 19 centres in Canada, USA, Greec

50 gnosis of either clear cell or papillary RCC renal cell carcinoma at pathologic analysis, who underwe

51 Among patients with locoregional clear-cell renal-cell carcinoma at high risk for tumor recurrence a

52 y of sunitinib in patients with locoregional renal-cell carcinoma at high risk for tumor recurrence a

53 increasingly important in the management of renal-cell carcinoma, both in primary settings and in tr

54 Sorafenib is an effective treatment for renal cell carcinoma, but recent clinical reports have d

55 infiltrate in human lung adenocarcinomas and renal cell carcinomas can be reliably dissected with mas

56 A subset of patients with metastatic renal-cell carcinoma can safely undergo surveillance bef

57 Clear cell renal cell carcinoma (CC-RCC) is the most lethal of all

58 otein pVHL is commonly mutated in clear cell renal cell carcinoma (ccRCC) and has been implicated in

59 nce analysis in two cancer types, clear cell renal cell carcinoma (ccRCC) and prostate adenocarcinoma

60 3) channel promotes the growth of clear cell renal cell carcinoma (ccRCC) and stimulates MAP1LC3A (LC

61 CP1 and SCP3 are downregulated in clear cell renal cell carcinoma (ccRCC) and these events correlated

62 mask (VAM) in H&E micrographs of clear cell renal cell carcinoma (ccRCC) cases from The Cancer Genom

63 In agreement, SETD2-mutant clear cell renal cell carcinoma (ccRCC) cells displayed impaired DN

64 esence of sarcomatoid features in clear cell renal cell carcinoma (ccRCC) confers a poor prognosis an

65 Clear cell renal cell carcinoma (ccRCC) has been previously classif

66 n of chromatin-modifying genes in clear cell renal cell carcinoma (ccRCC) has been uncovered through

67 However, its role in clear cell renal cell carcinoma (ccRCC) has not been described prev

68 ecent genomic studies of sporadic clear cell renal cell carcinoma (ccRCC) have uncovered novel driver

69 Clear-cell renal cell carcinoma (ccRCC) is a common aggressive urin

70 Clear cell renal cell carcinoma (ccRCC) is a gender-biased tumor.

71 infiltration score and find that clear cell renal cell carcinoma (ccRCC) is among the highest for bo

72 Clear cell renal cell carcinoma (ccRCC) is an aggressive tumor with

73 Clear cell renal cell carcinoma (CCRCC) is an incurable malignancy

74 Clear cell renal cell carcinoma (ccRCC) is characterized by inactiv

75 Clear cell renal cell carcinoma (ccRCC) is characterized by loss of

76 Clear cell renal cell carcinoma (CCRCC) is characterized by mutatio

77 Importantly, clear-cell renal cell carcinoma (ccRCC) is frequently associated wi

78 Clear cell renal cell carcinoma (ccRCC) is histologically defined b

79 Clear cell renal cell carcinoma (ccRCC) is the most common subtype

80 Clear cell renal cell carcinoma (ccRCC) is the most common tumor of

81 Clear cell renal cell carcinoma (ccRCC) is the most common type of

82 Human clear cell renal cell carcinoma (ccRCC) is therapy resistant; there

83 Surgery for clear-cell renal cell carcinoma (ccRCC) might benefit from the use

84 growth in selected VHL-deficient clear-cell renal cell carcinoma (ccRCC) models.

85 mune profiling of samples from 73 clear cell renal cell carcinoma (ccRCC) patients and five healthy c

86 (HIF) signaling pathway promotes clear cell renal cell carcinoma (ccRCC) progression and metastasis.

87 g from the kidney in adults, with clear cell renal cell carcinoma (ccRCC) representing approximately

88 ofiling of a cohort of 50 primary clear cell renal cell carcinoma (ccRCC) samples from The Cancer Gen

89 aled to be downregulated in human clear cell renal cell carcinoma (ccRCC) samples, which was also ver

90 studies have demonstrated that in clear cell renal cell carcinoma (ccRCC) several chromatin remodelin

91 On the other hand, clear cell renal cell carcinoma (ccRCC) strongly deviated in terms

92 -Lindau (VHL) are major causes of clear-cell renal cell carcinoma (ccRCC) that may originate from chr

93 ompounds with high selectivity to clear cell renal cell carcinoma (ccRCC) with common mutations.

94 an important prognostic factor of clear cell renal cell carcinoma (ccRCC), as well as a factor in gui

95 In the most common form of RCC, clear cell renal cell carcinoma (ccRCC), inactivation of the von Hi

96 Some cancers, such as clear cell renal cell carcinoma (ccRCC), require exogenous glutamin

97 Clear cell renal cell carcinoma (ccRCC), the most common form of ki

98 arly event in almost all cases of clear cell renal cell carcinoma (ccRCC), the most frequent form of

99 For clear cell renal cell carcinoma (ccRCC), three of the five commonly

100 protein ubiquitously expressed in clear cell renal cell carcinoma (ccRCC).

101 H has previously been reported in clear cell renal cell carcinoma (ccRCC).

102 or African American patients with clear cell renal cell carcinoma (ccRCC).

103 ene mutations are associated with clear cell renal cell carcinoma (ccRCC).

104 n and malignant tumors, including clear-cell renal cell carcinoma (ccRCC).

105 iR-204 and miR-210 related to the clear cell Renal Cell Carcinoma (ccRCC).

106 transcriptional target of HIFs in clear cell renal cell carcinoma (ccRCC).

107 uding both sporadic and inherited clear cell renal cell carcinoma (ccRCC).

108 sor VHL, the most common event in clear cell renal cell carcinoma (ccRCC).

109 BDs and is frequently mutated in clear cell renal cell carcinoma (ccRCC).

110 le in improving the management of clear cell renal cell carcinoma (ccRCC).

111 implicated in the pathogenesis of clear cell renal cell carcinoma (ccRCC).

112 lopment of adjuvant treatments in clear-cell renal cell carcinoma (ccRCC).

113 nsferase, have been identified in clear cell renal cell carcinoma (ccRCC); however it is unclear if l

114 ntly inactivated in patients with clear cell renal cell carcinoma (ccRCC); however, it is largely unk

115 pes from The Cancer Genome Atlas: clear cell renal cell carcinoma (ccRCC, also known as kidney renal

116 More than 90% of clear cell renal cell carcinomas (ccRCC) exhibit inactivation of th

117 is inactivated in the majority of clear cell renal cell carcinomas (ccRCC), but genetic ablation of V

118 VHL-deficient clear cell renal cell carcinomas (ccRCC), the most common form of k

119 h drives abnormal angiogenesis in clear cell renal cell carcinomas (ccRCC).

120 Clear cell renal cell carcinomas (ccRCCs) are characterized by bial

121 Clear cell renal cell carcinomas (ccRCCs) display divergent clinica

122 A subset of familial and sporadic clear cell renal cell carcinomas (ccRCCs) is believed to develop fr

123 is inactivated in the majority of clear cell renal cell carcinomas (ccRCCs), leading to inappropriate

124 pVHL-defective clear cell renal cell carcinoma cell lines display unexpectedly var

125 Intriguingly, clear cell renal cell carcinoma cells (ccRCC) have a dysregulated l

126 ne treatment in a xenograft model using ACHN renal cell carcinoma cells did not differ from vehicle c

127 A related effect has also been observed in renal cell carcinoma cells.

128 fically suppressed growth in patient-derived renal-cell carcinoma cells with endogenous PIK3Cbeta(D10

129 omatic genomic alterations of 66 chromophobe renal cell carcinomas (ChRCCs) on the basis of multidime

130 Furthermore, type 2 papillary renal-cell carcinoma consisted of at least three subtype

131 ght to validate the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) model in

132 te or poor risk per International Metastatic Renal Cell Carcinoma Database Consortium criteria.

133 nfiltrated lymphocytes from 16 patients with renal cell carcinoma demonstrated 56% of a strong tumor-

134 the transcription factor HNF4A in clear cell renal cell carcinoma, despite no differential expression

135 didate identified was the hepatocellular and renal cell carcinoma drug sorafenib.

136 characterization of the genome of clear cell renal cell carcinoma enabled identification of the roles

137 had been functionally disabled in the human renal cell carcinoma environment without unleashing unde

138 th treatment-naive, asymptomatic, metastatic renal-cell carcinoma from five hospitals in the USA, Spa

139 cy in other patient tumor samples (including renal cell carcinoma, glioblastoma multiforme, head and

140 ed melanoma, non-small cell lung cancer, and renal cell carcinoma has hastened the need to better cha

141 Renal cell carcinoma has long been understood to have a

142 systemic therapy in patients with metastatic renal cell carcinoma have not been studied in the settin

143 INTERPRETATION: Renal cell carcinomas have the highest pan-cancer propor

144 iforme, breast, colorectal, skin, clear cell renal cell carcinoma, hepatic and prostate cancer.

145 nesis has had some success in tumors such as renal cell carcinoma; however, angiogenesis inhibitors h

146 ary and metastatic pVHL-defective clear cell renal cell carcinoma in an on-target fashion.

147 tudies on local treatment of metastases from renal cell carcinoma in any organ.

148 resent the case of endovascular treatment of renal cell carcinoma in patient with solitary kidney.

149 ogenic agents that are effective in advanced renal-cell carcinoma, in patients with resected local di

150 Renal cell carcinoma is an interesting tumor due to its

151 tocrine/paracrine signaling in patients with renal cell carcinoma is associated with poor prognosis o

152 suppress ccRCC progression.The incidence of renal cell carcinoma is higher in males than in females

153 Renal cell carcinoma is the most common form of kidney c

154 Currently, metastatic renal cell carcinoma is treated with sequential single a

155 ce after nephrectomy in localised clear cell renal cell carcinoma is well characterised by clinical a

156 Renal-cell carcinoma is considered to be a radioresistan

157 Renal-cell carcinoma is highly vascular, and proliferate

158 cRNA-SARCC (Suppressing Androgen Receptor in Renal Cell Carcinoma) is differentially regulated by hyp

159 l carcinoma, which accounts for 15 to 20% of renal-cell carcinomas, is a heterogeneous disease that c

160 older with advanced or metastatic clear-cell renal cell carcinoma, measurable disease, and previous t

161 presence of BAP1-associated cancers such as renal cell carcinoma, mesothelioma and meningioma, but n

162 s for antiangiogenic treatment of metastatic renal cell carcinoma (mRCC) exist.

163 cytoreductive nephrectomy (CN) in metastatic renal cell carcinoma (mRCC) has become unclear since the

164 Metastatic renal cell carcinoma (mRCC) is nearly incurable and acco

165 ict the efficacy of everolimus in metastatic renal cell carcinoma (mRCC) patients are lacking.

166 is a standard initial therapy in metastatic renal cell carcinoma (mRCC), but chronic dosing requires

167 us a tyrosine kinase inhibitor in metastatic renal cell carcinoma (mRCC).

168 ety of nivolumab in patients with metastatic renal cell carcinoma (mRCC).

169 iogenic therapy is efficacious in metastatic renal cell carcinoma (mRCC).

170 standard second-line therapy for metastatic renal cell carcinoma (mRCC).

171 2%]), cutaneous melanoma (n = 38 [18%]), and renal cell carcinoma (n = 20 [9%]).

172 6.57; P < .001) in patients with melanoma or renal cell carcinoma (N = 60) than lung cancer (N = 153)

173 ncluded renal oncocytomas and non-clear cell renal cell carcinomas (nccRCCs), consisting of papillary

174 argeted therapies in advanced non-clear cell renal cell carcinoma (ncRCC) compared with clear cell re

175 Renal cell carcinoma of clear-cell type (ccRCC) is an en

176 many advances in the treatment of metastatic renal cell carcinoma of the clear cell type.

177 oma, but not in another approved malignancy, renal cell carcinoma, or when data were pooled across al

178 Although some tumours such as renal cell carcinoma, ovarian and cervical cancers, and

179 a phase 2 study in patients with metastatic renal cell carcinoma, overall survival was associated wi

180 d tissues from patients and murine models of renal cell carcinoma, pancreatic ductal adenocarcinoma,

181 Studies in metastatic renal cell carcinoma patients showed that everolimus pro

182 clinical trials of patients with metastatic renal-cell carcinoma, patients treated with axitinib as

183 Purpose Patients with advanced papillary renal cell carcinoma (PRCC) have limited therapeutic opt

184 Papillary renal cell carcinoma (pRCC) is an important subtype of k

185 he histomorphological subtyping of papillary renal cell carcinomas (pRCCs) has improved the predictio

186 come in patients with stage I-III clear cell renal cell carcinoma, providing a more accurate and indi

187 ently mutated in a significant percentage of renal cell carcinomas, raising the possibility that the

188 Renal cell carcinoma (RCC) - also known as hypernephroma

189 Renal cell carcinoma (RCC) accounts for several percent

190 The appropriate duration of surveillance for renal cell carcinoma (RCC) after radical or partial neph

191 cipients, for example, have a 7-fold risk of renal cell carcinoma (RCC) and 3-fold risk of urothelial

192 writing (EW) intervention for patients with renal cell carcinoma (RCC) and identified a potential un

193 GF) signaling promotes tumor invasiveness in renal cell carcinoma (RCC) and other cancers.

194 ined that CCR4 was highly expressed in human renal cell carcinoma (RCC) biopsies and observed abnorma

195 r syndrome associated with susceptibility to renal cell carcinoma (RCC) caused by inactivating mutati

196 ippel-Lindau (VHL)-null 786-O, RCC4 and A498 Renal Cell Carcinoma (RCC) cell lines expressing high le

197 toreductive nephrectomies and SETD2 isogenic renal cell carcinoma (RCC) cell lines using chromatin im

198 in controlling motility and invasiveness of renal cell carcinoma (RCC) cells.

199 Renal cell carcinoma (RCC) continues to be the subject o

200 For the past decade, advanced renal cell carcinoma (RCC) has been at the forefront of

201 morphisms (SNPs) associated with the risk of renal cell carcinoma (RCC) have been identified, yet gen

202 o diagnose malignant clear cell or papillary renal cell carcinoma (RCC) in a screening paradigm.

203 nephrectomy (PN) in the management of small renal cell carcinoma (RCC) in recent years has prompted

204 Renal cell carcinoma (RCC) is a cancer with poor prognos

205 Renal cell carcinoma (RCC) is a heterogeneous disease ma

206 Paediatric renal cell carcinoma (RCC) is a rare neoplasm which diff

207 Approximately 5% to 8% of renal cell carcinoma (RCC) is hereditary.

208 The incidence of renal cell carcinoma (RCC) is increasing worldwide, and

209 Renal cell carcinoma (RCC) is one of the most aggressive

210 Renal cell carcinoma (RCC) is polyresistant to chemo- an

211 Renal cell carcinoma (RCC) is the most common primary ca

212 Renal cell carcinoma (RCC) occurs in approximately 3% of

213 Renal cell carcinoma (RCC) of clear-cell type (ccRCC), t

214 As renal cell carcinoma (RCC) patients often present with o

215 Development of VHL-deficient renal cell carcinoma (RCC) relies upon activation of the

216 l carcinoma (ncRCC) compared with clear cell renal cell carcinoma (RCC) supports the study of combina

217 association studies have identified multiple renal cell carcinoma (RCC) susceptibility loci.

218 Furthermore, we showed previously that renal cell carcinoma (RCC) TGs retain the histology, gen

219 d long-term safety in patients with advanced renal cell carcinoma (RCC) treated with nivolumab in a p

220 pies, such as sunitinib, have revolutionized renal cell carcinoma (RCC) treatment.

221 lay an essential role in the pathogenesis of renal cell carcinoma (RCC) under normoxic conditions, th

222 noma, non-small cell lung cancer (NSCLC), or renal cell carcinoma (RCC) were eligible for a meta-anal

223 or proteinaceous cysts and 50 patients with renal cell carcinoma (RCC) were evaluated.

224 In renal cell carcinoma (RCC), cells deficient in the von H

225 ant endothelium collected from patients with renal cell carcinoma (RCC), colorectal carcinoma, or col

226 Kidney cancer, or renal cell carcinoma (RCC), is a disease of increasing i

227 form treatment choice in advanced/metastatic renal cell carcinoma (RCC), particularly between approve

228 ation to acquired resistance to sunitinib in renal cell carcinoma (RCC), providing a pre-clinical rat

229 Renal cell carcinoma (RCC), the third most prevalent uro

230 ctor-2alpha (HIF-2alpha)-dependent manner in renal cell carcinoma (RCC), yet the role of long noncodi

231 ccurs frequently in patients with metastatic renal cell carcinoma (RCC).

232 ging (DCE) in differentiation of subtypes of renal cell carcinoma (RCC).

233 giogenic therapy in patients with metastatic renal cell carcinoma (RCC).

234 ogrammed death-ligand 1 (PD-L1) antibody, in renal cell carcinoma (RCC).

235 s been identified as an important pathway in renal cell carcinoma (RCC).

236 ed to the development of targeted therapy in renal cell carcinoma (RCC).

237 requently mutated and overexpressed in human renal cell carcinoma (RCC).

238 ulating vitamin D is associated with risk of renal cell carcinoma (RCC).

239 uidelines for surveillance after surgery for renal cell carcinoma (RCC).

240 Dietary factors may affect risk of renal cell carcinoma (RCC).

241 nized the treatment of metastatic clear cell renal cell carcinoma (RCC).

242 pathway is a validated therapeutic target in renal cell carcinoma (RCC).

243 l heterogeneity in MB, malignant glioma, and renal cell carcinoma (RCC).

244 alue of MPV in the prognostic evaluations of renal cell carcinoma (RCC).

245 and breast, but its role remains unclear in renal cell carcinoma (RCC).

246 therapy given as a first-line treatment for renal cell carcinoma (RCC).

247 lid tumors was followed by dose expansion in renal cell carcinoma (RCC).

248 itical role in the growth and progression of renal cell carcinoma (RCC).

249 receptors PD-1 and Tim-3 from patients with renal cell carcinoma (RCC).

250 ies (GWAS) have identified six risk loci for renal cell carcinoma (RCC).

251 Kidney cancer [or renal cell carcinoma (RCC)] is known as "the internist's

252 mg/kg in patients with melanoma (n = 16) and renal cell carcinoma (RCC; n = 15).

253 Clear cell renal cell carcinomas (RCC) frequently display inactivat

254 hereas EMT contributes to the development of renal cell carcinomas (RCC).

255 sorafenib vs placebo in resected unfavorable renal cell carcinoma [RCC]), the largest adjuvant trial

256 nitially effective against kidney cancer (or renal cell carcinoma, RCC); however, drug resistance fre

257 for 100 consecutive biopsy-proved stage T1a renal cell carcinomas (RCCs) treated with percutaneous m

258 ar cell, 20 papillary, and seven chromophobe renal cell carcinomas [RCCs[) that were 1.1-4.0 cm in di

259 ium (IMDC) model in patients with metastatic renal cell carcinoma receiving next-line targeted therap

260 STAT3 are remarkably elevated in clear-cell renal-cell carcinoma relative to adjacent normal tissue,

261 trates in lung adenocarcinoma and clear cell renal cell carcinoma, respectively.

262 A subset of patients with metastatic renal-cell carcinoma show indolent growth of metastases.

263 ples from tumors of patients with clear cell renal cell carcinoma shows that increased CDCP1 expressi

264 effect of stereotactic body radiotherapy on renal-cell carcinoma, stereotactic body radiotherapy can

265 uencing of CDC and compared them to UTUC and renal cell carcinoma subtypes.

266 In patients with metastatic non-clear cell renal cell carcinoma, sunitinib improved progression-fre

267 surveillance, periodic self-examination, and renal cell carcinoma surveillance should be encouraged i

268 ell (tau = 0.85; P < .001) and papillary RCC renal cell carcinoma (tau = 0.53; P < .001).

269 TFE-fusion renal cell carcinomas (TFE-fusion RCCs) are caused by ch

270 ificant portion of aggressive non-clear cell renal cell carcinomas that have no standard therapy.

271 d in a distinct subgroup of type 2 papillary renal-cell carcinomas that was characterized by poor sur

272 Clear cell renal cell carcinoma, the most common form of kidney can

273 We observed renal cell carcinomas to have the highest proportion (0.

274 ents with locoregional, high-risk clear-cell renal-cell carcinoma to receive either sunitinib (50 mg

275 ogical rationale for the radiosensitivity of renal-cell carcinoma to stereotactic body radiotherapy b

276 rs; range, 19-83 years) with mRCC metastatic renal cell carcinoma treated with sunitinib from October

277 oi criteria in patients with mRCC metastatic renal cell carcinoma treated with sunitinib.

278 71.9 years +/- 10.9) with 217 biopsy-proven renal cell carcinoma tumors treated with thermal ablatio

279 systemic therapy in patients with metastatic renal-cell carcinoma under active surveillance.

280 human FLCN-deficient cell lines (BHD-origin renal cell carcinoma UOK257 and thyroid carcinoma FTC133

281 ar characterization of 161 primary papillary renal-cell carcinomas, using whole-exome sequencing, cop

282 ment-naive progressive metastatic clear cell renal cell carcinoma were enrolled between September 201

283 Adults with metastatic renal cell carcinoma were enrolled sequentially onto two

284 Patients with advanced renal cell carcinoma were randomly assigned (1:1, block

285 tic or locally advanced (or both) clear-cell renal cell carcinoma were randomly assigned (3:2) to rec

286 l of 361 patients with metastatic clear cell renal cell carcinoma were randomly assigned equally to a

287 Type 1 and type 2 papillary renal-cell carcinomas were shown to be clinically and bi

288 Type 1 and type 2 papillary renal-cell carcinomas were shown to be different types o

289 Papillary renal-cell carcinoma, which accounts for 15 to 20% of re

290 ents from France with stage I-III clear cell renal cell carcinoma who had also undergone nephrectomy.

291 tter than that of sorafenib in patients with renal cell carcinoma who had progressed on previous VEGF

292 in 942 patients with stage I-III clear cell renal cell carcinoma who had undergone a nephrectomy at

293 urvival benefit for patients with metastatic renal cell carcinoma who have progressed after one previ

294 cal need exists for patients with metastatic renal cell carcinoma who have progressed on VEGF-targete

295 hibitor everolimus in patients with advanced renal cell carcinoma who progressed after previous VEGFR

296 3 study, patients with clear cell metastatic renal cell carcinoma who received one previous VEGF-targ

297 y, previously treated patients with advanced renal cell carcinoma who were randomly assigned to nivol

298 chromophobe, or unclassified non-clear cell renal cell carcinoma with no history of previous systemi

299 standard first-line treatment in metastatic renal cell carcinoma with postulated favourable immunomo

300 Renal cell carcinomas with unclassified histology (uRCC)